| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
An open-label study of lapatinib in women with HER-2-negative early breast cancer: the lapatinib pre-surgical study (LPS study)
|
Coombes, R.C.
|
|
|
24 |
4 |
p. 924-930
|
artikel
|
| 2 |
A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer
|
Lee, C.K.
|
|
|
24 |
4 |
p. 937-943
|
artikel
|
| 3 |
A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group
|
Pautier, P.
|
|
|
24 |
4 |
p. 1099-1104
|
artikel
|
| 4 |
Are PubMed alone and English literature only enough for a meta-analysis?
|
Zheng, B.
|
|
|
24 |
4 |
p. 1130
|
artikel
|
| 5 |
Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17
|
Vickers, M.M.
|
|
|
24 |
4 |
p. 953-960
|
artikel
|
| 6 |
Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series †
|
Rodrigues, M.J.
|
|
|
24 |
4 |
p. 916-924
|
artikel
|
| 7 |
Blood pressure monitoring in patients receiving bevacizumab
|
Coriat, R.
|
|
|
24 |
4 |
p. 1127
|
artikel
|
| 8 |
Cancer in Africa: supporting advocates to stop the runaway train
|
Adamou, A.
|
|
|
24 |
4 |
p. 855-856
|
artikel
|
| 9 |
Comment on: management of chemotherapy extravasation: ESMO–EONS clinical practice guidelines
|
Conde-Estévez, D.
|
|
|
24 |
4 |
p. 1128-1129
|
artikel
|
| 10 |
Cruciferous vegetables intake and the risk of colorectal cancer: a meta-analysis of observational studies
|
Wu, Q.J.
|
|
|
24 |
4 |
p. 1079-1087
|
artikel
|
| 11 |
Disease volumes as a marker for patient response in malignant pleural mesothelioma
|
Labby, Z.E.
|
|
|
24 |
4 |
p. 999-1005
|
artikel
|
| 12 |
Dose escalation study of carboplatin–pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer
|
Tamiya, A.
|
|
|
24 |
4 |
p. 980-985
|
artikel
|
| 13 |
Editorial board
|
|
|
|
24 |
4 |
p. ii-iii
|
artikel
|
| 14 |
Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy †
|
Sternberg, C.N.
|
|
|
24 |
4 |
p. 1017-1025
|
artikel
|
| 15 |
Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial
|
Saito, H.
|
|
|
24 |
4 |
p. 1067-1073
|
artikel
|
| 16 |
Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial †
|
Advani, R.H.
|
|
|
24 |
4 |
p. 1044-1048
|
artikel
|
| 17 |
Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG–0803) †
|
Wu, Y.-L.
|
|
|
24 |
4 |
p. 993-999
|
artikel
|
| 18 |
ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma
|
Dreyling, M.
|
|
|
24 |
4 |
p. 857-877
|
artikel
|
| 19 |
Final height in survivors of childhood cancer compared with Height Standard Deviation Scores at diagnosis
|
Knijnenburg, S.L.
|
|
|
24 |
4 |
p. 1119-1126
|
artikel
|
| 20 |
Functional proteomics characterization of residual breast cancer after neoadjuvant systemic chemotherapy
|
Gonzalez-Angulo, A.M.
|
|
|
24 |
4 |
p. 909-916
|
artikel
|
| 21 |
Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial
|
Patrikidou, A.
|
|
|
24 |
4 |
p. 1087-1093
|
artikel
|
| 22 |
Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma
|
Romano, A.
|
|
|
24 |
4 |
p. 1038-1044
|
artikel
|
| 23 |
Irsogladine maleate reduces the incidence of fluorouracil-based chemotherapy-induced oral mucositis
|
Nomura, M.
|
|
|
24 |
4 |
p. 1062-1066
|
artikel
|
| 24 |
Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer
|
Beyer, J.
|
|
|
24 |
4 |
p. 878-888
|
artikel
|
| 25 |
mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE)
|
Prajapati, H.J.
|
|
|
24 |
4 |
p. 965-973
|
artikel
|
| 26 |
Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma †
|
Mita, M.M.
|
|
|
24 |
4 |
p. 1104-1111
|
artikel
|
| 27 |
Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B)
|
Ketterer, N.
|
|
|
24 |
4 |
p. 1032-1037
|
artikel
|
| 28 |
Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy
|
Santoro, A.
|
|
|
24 |
4 |
p. 1093-1098
|
artikel
|
| 29 |
Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma †
|
Xue, C.
|
|
|
24 |
4 |
p. 1055-1061
|
artikel
|
| 30 |
Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma
|
Koh, Y.
|
|
|
24 |
4 |
p. 1026-1031
|
artikel
|
| 31 |
Prevalence of depression in adults with cancer: a systematic review
|
Walker, J.
|
|
|
24 |
4 |
p. 895-900
|
artikel
|
| 32 |
Prognostic factors for survival after complete resections of synchronous lung cancers in multiple lobes: pooled analysis based on individual patient data
|
Tanvetyanon, T.
|
|
|
24 |
4 |
p. 889-894
|
artikel
|
| 33 |
Prognostic significance of metabolic response by positron emission tomography after neoadjuvant chemotherapy for resectable malignant pleural mesothelioma
|
Tsutani, Y.
|
|
|
24 |
4 |
p. 1005-1010
|
artikel
|
| 34 |
Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03)
|
Bamias, A.
|
|
|
24 |
4 |
p. 1011-1017
|
artikel
|
| 35 |
Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study
|
Kreuter, M.
|
|
|
24 |
4 |
p. 986-992
|
artikel
|
| 36 |
Reliability of core needle biopsy for determining ER and HER2 status in breast cancer
|
Dekker, T.J.A.
|
|
|
24 |
4 |
p. 931-937
|
artikel
|
| 37 |
Reply to ‘Comment on: management of chemotherapy extravasation: ESMO–EONS clinical practice guidelines'
|
Pérez-Fidalgo, J.A.
|
|
|
24 |
4 |
p. 1129-1130
|
artikel
|
| 38 |
Response to letter titled: blood pressure monitoring in patients receiving bevacizumab
|
Shah, S.R.
|
|
|
24 |
4 |
p. 1127-1128
|
artikel
|
| 39 |
Risk factors for non-cancer health events in patients with head and neck squamous cell carcinoma
|
Ryu, C.H.
|
|
|
24 |
4 |
p. 1049-1054
|
artikel
|
| 40 |
Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis
|
Tawbi, H.A.
|
|
|
24 |
4 |
p. 1112-1119
|
artikel
|
| 41 |
Shorter bevacizumab infusions do not increase the incidence of proteinuria and hypertension
|
Shah, S.R.
|
|
|
24 |
4 |
p. 960-965
|
artikel
|
| 42 |
Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer
|
|
|
|
24 |
4 |
p. 1133
|
artikel
|
| 43 |
Table of Contents
|
|
|
|
24 |
4 |
p. iv-vii
|
artikel
|
| 44 |
The contribution of molecular epidemiology to the identification of human carcinogens: current status and future perspectives
|
Boffetta, P.
|
|
|
24 |
4 |
p. 901-908
|
artikel
|
| 45 |
The FACT-G7: a rapid version of the functional assessment of cancer therapy-general (FACT-G) for monitoring symptoms and concerns in oncology practice and research
|
Yanez, B.
|
|
|
24 |
4 |
p. 1073-1078
|
artikel
|
| 46 |
The need for accredited training in gynaecological oncology: a report from the European Network of Young Gynaecological Oncologists (ENYGO)
|
Manchanda, R.
|
|
|
24 |
4 |
p. 944-952
|
artikel
|
| 47 |
The predictive value of BRCA1 and RAP80 mRNA expression in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy
|
Bonanno, L.
|
|
|
24 |
4 |
p. 1130-1132
|
artikel
|
| 48 |
Treatment and complications in elderly stage III colon cancer patients in the Netherlands
|
Hoeben, K.W.J.
|
|
|
24 |
4 |
p. 974-979
|
artikel
|
Tijdschrift beschrijving